Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

NICE Guidance Supports Olaparib Use in BRCA-Mutant Breast, Prostate Cancer

April 7th 2023

The National Institute for Health and Care Excellence announced final draft guidance recommending the PARP inhibitor olaparib for patients with HER2-negative, high-risk early breast cancer harboring a BRCA1/2 mutation, as well as for those with previously treated hormone-relapsed metastatic prostate cancer with a BRCA1/2 mutation.

Importance of Quality of Life When Choosing Therapy for nmCRPC

April 5th 2023

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

AR Inhibitors in nmCRPC: Real-World Data

April 5th 2023

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

Dr Tombal on the Pharmacokinetics of Darolutamide Plus Docetaxel in mHSPC

April 4th 2023

Bertrand Tombal, MD, PhD, discusses the pharmacokinetics of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer.

Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer

April 3rd 2023

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.

TALAPRO-2 Data Underscore Potential of Talazoparib Plus Enzalutamide in mCRPC

March 29th 2023

Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.

nmCRPC: Clinical Trial Data on AR Inhibitors

March 29th 2023

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer

March 29th 2023

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Dr Sokolova on Rucaparib vs Physician’s Choice Therapy in BRCA+ mCRPC

March 27th 2023

Alexandra Sokolova, MD,discusses the evaluation of rucaparib vs physician’s choice standard of care therapy in patients with BRCA-positive metastatic castration-resistant prostate cancer.

Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors

March 24th 2023

The safety and efficacy of the immune checkpoint inhibitor atezolizumab plus the VEGF TKI tivozanib is being investigated in patients with unresectable or metastatic castrate-resistant prostate cancer, as well as those with several other immunologically cold tumors as part of the phase 1b/2 IMMCO-1 trial.

Dr Dreicer on the Potential Role of Triplet Therapy in De Novo Metastatic Prostate Cancer

March 22nd 2023

Robert Dreicer, MD, discusses the use of triplet therapy in the first-line management of de novo metastatic prostate cancer.

Key Unmet Needs in Prostate Cancer Management

March 22nd 2023

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

Recent Progress in the Prostate Cancer Treatment Landscape

March 22nd 2023

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

Enzalutamide Plus Leuprolide Improves MFS in Nonmetastatic Castration-Sensitive Prostate Cancer

March 17th 2023

Enzalutamide plus leuprolide demonstrated a statistically significant and clinically meaningful improvement in metastasis-free survival compared with placebo plus leuprolide in patients with nonmetastatic castration-sensitive prostate cancer with a high-risk of biochemical recurrence.

Dr. Yu on the Use of PARP Inhibitors and Radiopharmaceuticals in Prostate Cancer

March 16th 2023

Evan Y. Yu, MD, discusses new data and continuing conversations regarding the use of PARP inhibitors and targeted radioligand therapies in prostate cancer.

Dr. Carducci on the Ongoing CAPItello-280 Trial in mCRPC

March 16th 2023

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

The FDA has approved a supplementary new drug application for Illuccix for use in the selection of patients with metastatic prostate cancer for whom lutetium Lu 177 vipivotide tetraxetan is indicated.

Dr. Cookson on Understanding Predictive Features in the Management of Prostate Cancer

March 15th 2023

Michael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.

BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors

March 15th 2023

Bellicum Pharmaceuticals has discontinued 2 phase 1/2 trials evaluating the safety and preliminary efficacy of the GoCAR T-cell products BPX-601 and BPX-603 in combination with rimiducid in heavily pretreated patients with advanced solid tumors following an assessment of the risk/benefit profile of the combination of BPX-601 and rimiducid.

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Enzalutamide plus androgen deprivation therapy produced a statistically significant improvement in time to prostate-specific antigen progression compared with ADT and placebo in men with metastatic hormone-sensitive prostate cancer, meeting the primary end point of the phase 3 China ARCHES study.